Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Segment Reporting

The operating financial results of the Company’s R&D segment for the three months ended March 31, 2026 and 2025 are as follows (in thousands):

	Three Months Ended March 31,
	2026		2025
Revenue	$	1,294	$	858
Less: Significant segment expenses
Personnel-related expenses	5,875		5,187
Clinical and preclinical expenses	4,631		4,479
Facilities-related and overhead	1,793		1,976
Professional and consulting fees	1,471		1,601
Corporate expenses	340		581
Travel and entertainment	255		134
Plus: Other segment (loss) income	(5,260)		667
Segment net loss	$	(18,331)	$	(12,433)

Other segment income includes total other income, net on the condensed consolidated statements of operations.